CAS · 417716-92-8
Product Overview
Lenvatinib is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Character: | Off-white to white powder |
|---|---|
| Purity: | 99.0% min |
| Loss on drying: | 0.5% max |
| Residue on ignition: | 0.5% max |
| Unspecified impurity: | 0.2% max |
| Total impurities: | 1.0% max |
Applications
1. Cancer Treatment
Lenvatinib is a targeted anticancer drug used in the treatment of various solid tumors. It is approved for use in several types of advanced or metastatic cancers, including:
■ Thyroid Cancer
Approved for radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
Improves progression-free survival compared to placebo.
■ Hepatocellular Carcinoma (HCC)
Used as a first-line therapy for unresectable liver cancer.
Shown to be non-inferior to sorafenib in clinical trials (e.g., REFLECT trial).
■ Renal Cell Carcinoma (RCC)
Used in combination with everolimus or pembrolizumab for advanced RCC.
Offers improved objective response rate and overall survival.
■ Endometrial Cancer
Approved in combination with pembrolizumab for advanced or recurrent endometrial carcinoma not responsive to conventional therapy.
Benefits
1. Targeted Therapy
Specifically acts on cancer-driving pathways, minimizing damage to normal cells compared to traditional chemotherapy.
2. Broad Antitumor Activity
Effective across multiple cancer types due to its multi-target inhibition.
3. Oral Administration
Given as a daily oral capsule, which is more convenient than intravenous therapies.
4. Synergistic in Combination Therapy
Potentiates the efficacy of immunotherapies (e.g., pembrolizumab), enabling combinatorial treatment approaches.
5. Improved Clinical Outcomes
Increases progression-free survival (PFS) and overall response rate (ORR) in several cancer types.
Often a first-line choice when surgery is not feasible or disease is refractory to standard care.
Conclusion
Lenvatinib (CAS 417716-92-8) is a potent, multi-targeted kinase inhibitor used in modern oncology. It plays a critical role in the treatment of thyroid, liver, kidney, and endometrial cancers by inhibiting angiogenesis and tumor cell proliferation. Its effectiveness, particularly when combined with immunotherapy, makes it a cornerstone in the management of several difficult-to-treat cancers.
Previous
Next